Cutaneous manifestations of internal malignancy: Diagnosis and management

American Journal of Clinical Dermatology

Volumn 7, Issue 2, 2006, Pages 71-84

  Kleyn, C Elise ^a   Lai Cheong, Joey E ^a   Bell, Hazel K ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; NICOTINIC ACID; OCTREOTIDE; PREDNISOLONE; SOMATOSTATIN; SULFAPYRIDINE; SULFONAMIDE; TACROLIMUS;

ACANTHOSIS NIGRICANS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; BASAL CELL NEVUS SYNDROME; BAZEX SYNDROME; CANCER INVASION; CANCER SUSCEPTIBILITY; CARCINOID SYNDROME; CAUSE OF DEATH; CLINICAL FEATURE; COLON ADENOCARCINOMA; COWDEN SYNDROME; DERMADROME; DERMATOMYOSITIS; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENCY; ERYTHEMA; FAMILIAL POLYPOSIS; GARDNER SYNDROME; GENETIC DISORDER; HUMAN; ICHTHYOSIS; KERATOSIS; KERATOSIS PALMOPLANTARIS; LESER TRELAT; MUIR TORRE SYNDROME; NEUROFIBROMATOSIS; NONHUMAN; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PEMPHIGOID; PEUTZ JEGHERS SYNDROME; PREVALENCE; PRIORITY JOURNAL; PRURITUS; PYODERMA GANGRENOSUM; REVIEW; SCLERODERMA; SCREENING; SEBORRHEIC KERATOSIS; SKIN CANCER; SKIN METASTASIS; TUBEROUS SCLEROSIS; TYLOSIS; UNSPECIFIED SIDE EFFECT; VASCULITIS; VESICULAR RASH; XEROSIS;

HUMANS; NEOPLASMS; PARANEOPLASTIC SYNDROMES; SKIN DISEASES; SKIN NEOPLASMS;

EID: 33645894960     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607020-00001     Document Type: Review

References (149)

1. Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of internal carcinoma: a retrospective study of 7316 cancer patients. J Am Acad Dermatol 1990; 22: 19-26
2. Spencer PS, Helm TN. Skin metastases in cancer patients. Cutis 1987; 39: 119-21
3. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol 1993; 29: 228-36
4. Weedon D. Cutaneous metastases. In: Weedon D, editor. Skin pathology. Edinburgh: Churchill Livingstone, 1997: 855-64
5. Brownstein MH, Helwig EB. Patterns of cutaneous metastases. Arch Dermatol 1972; 105: 862-8
6. Brenner S, Tamir E, Maharshak N, et al. Cutaneous manifestations of internal malignancies. Clin Dermatol 2001; 19: 290-7
7. Gmitter TI, Dhawan SS, Phillips MG, et al. Cutaneous metastases of colonic adenocarcinoma. Cutis 1990; 46: 66-8
8. McLean DI. Cutaneous paraneoplastic syndromes. Arch Dermatol 1986; 122: 765-7
9. Barnes BE, Mawr B. Dermatomyositis and malignancy: a review of the literature. Ann Intern Med 1976; 84: 68-76
10. Henriksson KG, Sandstedt P. Polymyositis: treatment and prognosis: a study of 107 patients. Acta Neurol Scand 1982; 65: 280-300
11. Airio A, Pukkala E, Isomali H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995; 22: 1300-3
12. Sigurgeiersson B, Lindelof B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992; 326: 363-7
13. Kalmanti M, Athanasion A. Neuroblastoma occurring in a child with dermatomyositis. Am J Pediatr Hematol Oncol 1985; 7: 387-8
14. Graham RM, Cox NH. Systemic disease and the skin. In: Burns T, Breathnach S, Cox N, et al., editors. Rook's textbook of dermatology. 7th ed. Oxford: Blackwell Science, 2004: 59.1-59.75
15. Cox NH, Lawrence CM, Langry JA, et al. Dermatomyositis: disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol 1990; 126: 61-5
16. Callen JP. When and how should the patient with dermatomyositis or amyopathic dermatomyositis be assessed for possible cancer? Arch Dermatol 2002; 138: 969-71
17. Sparsa A, Liozon E, Hermann F, et al. Routine vs extensive malignancy search for adult dermatomyositis and polymyositis. Arch Dermatol 2002; 138: 885-90
18. Woo TY, Callen JP, Voorhees JJ, et al. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol 1984; 10: 592-600
19. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol 2000; 27: 1542-5
20. Choy EHS, Hoogendijk JE, Lecky B, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005; (3): CD003643.pub2
21. Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica): an analytic review. Medicine (Baltimore) 1991; 70: 269-80
22. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol 1995; 14: 84-9
23. Akhyani M, Mansoori P, Taheri A, et al. Acrokeratosis paraneoplastica (Bazex syndrome) associated with breast cancer. Clin Exp Dermatol 2004; 29: 429-30
24. Weedon D. Miscellaneous conditions. In: Weedon D, editor. Skin pathology. Edinburgh: Churchill Livingstone, 1997: 482-87
25. Cohen PR, Kurzrock R. Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 2003; 42: 761-78
26. Chan HL, Lee YS, Kuo TT. Sweet's syndrome: clinicopathologic study of eleven cases. Int J Dermatol 1994; 33: 425-32
27. Soppi E, Nousiainen T, Seppa A, et al. Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: a report of three cases and a review of the literature. Br J Haematol 1989; 73: 43-7
28. Fitzpatrick TB, Johnson RA, Wolff K, et al. Miscellaneous inflammatory disorders. In: Fitzpatrick TB, Johnson RA, Wolff K, et al., editors. Color atlas and synopsis of clinic dermatology. New York (NY): McGraw-Hill, 2001: 106-51
29. Graham JA, Hansen KK, Rabinowitz LG, et al. Pyoderma gangrenosum in infants and children. Pediatr Dermatol 1994; 11: 10-7
30. Kurzrock R, Cohen PR. Mucocutaneous paraneoplastic manifestations of hematologic malignancies (review). Am J Med 1995; 99: 207-16
31. Chow RKP, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34: 1047-60
32. Lindelof B, Islam N, Eklund G, et al. Pemphigoid and cancer. Arch Dermatol 1990; 126: 66-8
33. Venning VA, Wojnarowska F. The association of bullous pemphigoid and malignant disease: a case control study. Br J Dermatol 1990; 123: 439-45
34. Egan CA, Lazarova Z, Darling TN, et al. Antiepiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357: 1850-1
35. Kimyai-Asadi A, Jin MH. Paraneoplastic pemphigus. Int J Dermatol 2001; 40: 367-72
36. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729-35
37. Bronnimann M, von Felbert V, Streit M, et al. Progressive respiratory failure in paraneoplastic pemphigus associated with chronic lymphocytic leukemia. Dermatology 2004; 208: 251-4
38. Kaplan I, Hodak E, Ackerman L, et al. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncology 2004; 40: 553-62
39. Weedon D. The vesicobullous reaction pattern. In: Weedon D, editor. Skin pathology. Edinburgh: Churchill Livingstone, 1997: 109-59
40. White JW, Perry HO. Erythema perstans. Br J Dermatol 1969; 81: 641-51
41. Skolnick M, Mainman ER. Erythema gyratum repens with metastatic adenocarcinoma. Arch Dermatol 1975; 111: 227-9
42. Barber PV, Doyle L, Vickers DM, et al. Erythema gyratum repens with pulmonary tuberculosis. Br J Dermatol 1978; 98: 465-8
43. Breathnach SM, Wilkinson JD, Black MM. Erythema gyratum repens-like figurate eruption in bullous pemphigoid. Clin Exp Dermatol 1982; 7: 401-6
44. Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci 2001; 321: 459-81
45. Kawakami T, Saito R. Erythema gyratum repens unassociated with underlying malignancy. J Dermatol 1995; 22: 587-9
46. Caux F, Lebbe C, Thomine E, et al. Erythema gyratum repens: a case studied with immunofluorescence, immunoelectron microscopy and immunohistochemistry. Br J Dermatol 1994; 131: 102-7
47. Holt PJ, Davies MG. Erythema gyratum repens: an immunologically mediated dermatosis? Br J Dermatol 1977; 96: 343-7
48. Weedon D. Vasculopathic reaction pattern. In: Weedon D, editor. Skin pathology. Edinburgh: Churchill Livingstone, 1997: 408-9
49. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001; 321: 306-20
50. Weedon D. Metabolic and storage diseases. In: Weedon D, editor. Skin pathology. Edinburgh: Churchill Livingstone, 1997: 109-59
51. El Rassi Z, Partensky C, Valette PJ, et al. Necrolytic migratory erythema, first symptom of a malignant glucagonoma: treatment by long-acting somatostatin and surgical resection: report of three cases. Eur J Surg Oncol 1998; 24: 562-7
52. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V. Cutaneous vasculitis in children and adults: associated diseases and etiologic factors in 303 patients. Medicine 1998; 77: 403-18
53. Greer JM, Longley S, Edwards NL, et al. Vasculitis associated with malignancy: experience with 13 patients and literature review. Medicine (Baltimore) 1988; 67: 220-30
54. Trent JT, Kirsner RS. Vasculitis: a precis. Adv Skin Wound Care 2001: 14: 64-70
55. Longley S, Caldwell JR, Panush RS. Paraneoplastic vasculitis: unique syndrome of cutaneous angiitis and arthritis associated with myeloproliferative disorders. Am J Med 1986; 80: 1027-30
56. Sanchez-Guerrero J, Gutierrez-Urena S, Vidaller A. Vasculitis as a paraneoplastic syndrome: report of 11 cases and review of the literature. J Rheumatol 1990; 17: 1458-62
57. Agarwala SS. Paraneoplastic syndromes. Med Clin North Am 1996; 80: 173-84
58. Highet A. Urticarial vasculitis and IgA myeloma. Br J Dermatol 1980; 102: 355-7
59. Lewis JE. Urticarial vasculitis occurring in association with visceral malignancy. Acta Derm Venereol 1990; 70: 345-7
60. Sprossman A, Muller RP. Urticaria-vasculitis syndrome in metastatic malignant testicular teratoma. Hautarzt 1994; 45: 871-4
61. Wilson D, McCluggage WG, Wright GD. Urticarial vasculitis: a paraneoplastic presentation of B-cell non-Hodgkin's lymphoma. Rheumatology 2002; 41: 476-7
62. Ducarme G, Rey D, Bryckaert PE, et al. Paraneoplastic urticarial vasculitis and renal carcinoma. Prog Urol 2003; 13: 495-7
63. Kurzrock R, Cohen PR, Markowitz A. Clinic manifestations of vasculitis in patients with solid tumors: a case report and review of the literature. Arch Intern Med 1994; 154: 334-40
64. Lacour JP, Castanet J, Perrin C, et al. Cutaneous leukocytoclastic vasculitis and renal cancer: two cases. Am J Med 1993; 94: 104-8
65. Odeh M, Misselevich I, Oliven A. Squamous cell carcinoma of the lung presenting with cutaneous leukocytoclastic vasculitis: a case report. Angiology 2001; 52: 641-4
66. Schwartz RA, Williams ML. Acquired ichthyosis: a marker for internal disease. Am Fam Physician 1984; 29: 181-4
67. Aram H. Acquired ichthyosis and related conditions. Int J Dermatol 1984; 23: 458-61
68. Ameen M, Chopra S, Darvay A, et al. Erythema gyratum repens and acquired ichthyosis associated with transitional cell carcinoma of the kidney. Clin Exp Dermatol 2001; 26: 510-2
69. Kato N, Yasukawa K, Kimura K, et al. Anaplastic large-cell lymphoma associated with acquired ichthyosis. J Am Acad Dermatol 2000; 42: 914-20
70. Roselino AM, Souza CS, Andrade JM, et al. Dermatomyositis and acquired ichthyosis as paraneoplastic manifestations of ovarian tumor. Int J Dermatol 1997; 36: 611-4
71. DiGiovanna JJ. Ichthyosiform dermatoses. In: Freedberg IM, Eisen AZ, Wolff K, et al., editors. Fitzpatrick's dermatology in general medicine. New York (NY): McGraw Hill, 1999: 594-5
72. Engin H, Akdogan A, Altundag O. Non-small-cell lung cancer with nonfamilial diffuse palmoplantar keratoderma. J Exp Clin Cancer Res 2002; 21: 45-7
73. Smith CH, Barker JN, Hay RJ. Diffuse plane xanthomatosis and acquired palmoplantar keratoderma in association with myeloma. Br J Dermatol 1995; 132: 286-9
74. Cruz P, Hud J. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98: 82-5
75. Pentenero M, Carrozzo M, Pagano M, et al. Oral acanthosis nigricans, tripe palms and sign of Leser-Trelat in a patient with gastric adenocarcinoma. Int J Dermatol 2004; 43: 530-2
76. Sabai G, Grant JM, Kurtz R, et al. Cutaneous manifestation of internal malignancies (I). Acanthosis nigricans. Int J Dermatol 1978; 17: 312-5
77. Moller H, Eriksson S, Holen O, et al. Complete reversibility of paraneoplastic acanthosis nigricans after operation. Acta Med Scand 1978; 203: 245-6
78. Dantzig PI. Sign of Leser-Trelat. Arch Dermatol 1973; 108: 700-1
79. Williams MG. Acanthomata appearing after eczema. Br J Dermatol 1956; 68: 268-71
80. Feingold KR, Elias PM. Endocrine-skin interactions: cutaneous manifestations of adrenal disease, pheochromocytomas, carcinoid syndrome, sex hormone excess and deficiency, polyglandular autoimmune syndromes, multiple endocrine neoplasia syndromes, and other miscellaneous disorders. J Am Acad Dermatol 1988; 19: 1-20
81. Zeitlin IJ, Smith AN. 5-Hydroxyindoles and kinins in the carcinoid and dumping syndromes. Lancet 1966; 2: 986-91
82. Smith AG, Greaves MW. Blood prostaglandin activity associated with noradrenaline-provoked flush in the carcinoid syndrome. Br J Dermatol 1974; 90: 547-51
83. Greaves MW. Flushing and flushing syndromes, rosacea and perioral dermatitis. In: Champion RH, Burton JL, Burns DA, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. Oxford: Blackwell Science, 1998: 2099-2113
84. Altman AR, Tschen JA, Rice L. Treatment of malignant carcinoid syndrome with a long-acting somatostatin analogue. Arch Dermatol 1989; 125: 394-6
85. Shah GM, Shah RG, Veilette H, et al. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am J Gastroenterol 2005; 100: 2307-14
86. Zarafonetis CJD, Lorber SM, Manson SM. Association of functioning carcinoid syndrome and scleroderma. I: case report. Am J Med Sci 1958; 236: 1-14
87. Ratnavel RC, Burrows NP, Pye RJ. Scleroderma and the carcinoid syndrome. Clin Exp Dermatol 1994; 19: 83-5
88. Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature 1988; 335: 254-6
89. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 2001; 10: 827-31
90. Handley J, Walsh M, Armstrong K, et al. Malignant carcinoid syndrome associated with cutaneous scleroderma. Br J Dermatol 1993; 129: 222-3
91. Pavlovic M, Saiag P, Lotz P, et al. Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide. Arch Dermatol 1995; 131: 1207-9
92. Mallory SB. Other genodermatoses. In: Bolognia JL, Jorizzo JL, Rapini RP, et al., editors. Dermatology. Toronto (Canada): Elsevier Limited, 2003: 892-3
93. Lynch HT, Fusaro RM, Roberts L, et al. Muir-Torre syndrome in several members of a family with a variant of the cancer family syndrome. Br J Dermatol 1985; 113: 295-301
94. Lynch HT, Lynch PM, Pester J, et al. The cancer family syndrome: rare cutaneous phenotypic linkage of Torre's syndrome. Arch Intern Med 1981; 141: 607-11
95. Popnikolov NK, Gatalica Z, Colome-Grimmer MI, et al. Loss of mismatch repair protein in sebaceous gland tumors. J Cutan Pathol 2003; 30: 178-84
96. Serleth HJ, Kisken WA. A Muir-Torre syndrome family. Am Surg 1998; 64 (4): 365-9
97. Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol 1995; 33: 90-104
98. el Nakadi B, Nouwynck C, Salhadin A. Combined therapeutic approach for extraorbital sebaceous carcinoma in a Torre's syndrome. Eur J Surg Oncol 1995; 21: 321-2
99. Schwartz RA, Goldberg DJ, Mahmood F, et al. The Muir-Torre syndrome: disease of sebaceous and colonic neoplasms. Dermatologica 1989; 178: 23-8
100. Cohen PR, Kohn SR, Davis DA, et al. Muir-Torre syndrome. Dermatol Clin 1995; 13: 79-89
101. Inoshita T, Youngberg GA. Keratoacanthomas associated with cervical squamous cell carcinoma. Arch Dermatol 1984; 120: 123-4
102. Yohay K. Neurofibromatosis types 1 and 2. Neurologist 2006; 12: 86-93
103. Barker D, Wright E, Nguyen K, et al. A genomic search for linkage of neurofibromatosis to RFLPs. J Med Genet 1987; 24: 536-8
104. Collins FS, Ponder BA, Seizinger BR, et al. The von Recklinghausen neurofibromatosis region on chromosome 17: genetic and physical maps come into focus. Am J Hum Genet 1989; 44: 1-5
105. Raevaara TE, Gerdes AM, Lonnqvist KE, et al. HNPCC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1. Genes Chromosomes Cancer 2004; 40: 261-5
106. Hasanreisoglu B, Or M, Akbatur H. Neurofibromatosis associated with retinoblastoma: case report. Br J Ophthalmol 1988; 72: 139-41
107. Duve S, Rakoski J. Cutaneous melanoma in a patient with neurofibromatosis: case report and review of the literature. Br J Dermatol 1994; 131: 290-4
108. Friedman SM, Margo CE. Choroidal melanoma and neurofibromatosis type 1. Arch Ophthalmol 1998; 116: 694-5
109. Bernadis V, Sorrentino D, Snidero D, et al. Intestinal leiomyosarcoma and gastroparesis associated with von Recklinghausen's disease. Digestion 1999; 60: 82-5
110. Martinez-Lage JF, Salcedo C, Corral M, et al. Medulloblastomas in neurofibromatosis type 1: case report and literature review. Neurocirugia (Astur) 2002; 13: 128-31
111. Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. Adv Neurol 1981; 29: 33-56
112. Rosser T, Packer RJ. Intracranial neoplasms in children with neurofibromatosis 1. J Child Neurol 2002; 17: 630-7
113. Ceccaroni M, Genuardi M, Legge F, et al. BRCA1-related malignancies in a family presenting with von Recklinghausen's disease. Gynecol Oncol 2002; 86: 375-8
114. al-Gazali LI, Arthur RJ, Lamb JT, et al. Diagnostic and counselling difficulties using a fully comprehensive screening protocol for families at risk for tuberous sclerosis. J Med Genet 1989; 26: 694-703
115. Connor JM, Sampson J. Recent linkage studies in tuberous sclerosis: chromosome 9 markers. Ann N Y Acad Sci 1991; 615: 265-73
116. Kandt RS, Haines JL, Smith M, et al. Linkage of an important gene locus for tuberous sclerosis to a chromosome 16 marker for polycystic kidney disease. Nat Genet 1992; 2: 37-41
117. Rose VM. Neurocutaneous syndromes. Mo Med 2004; 101: 112-6
118. Harper JI, Trembath RC. Genetics and genodermatoses. In: Burns T, Breathnach S, Cox N, et al., editors. Rook's textbook of dermatology. 7th ed. Oxford: Blackwell Science, 2004: 12.1-12.85
119. Smith HC, Watson GH, Patel RG, et al. Cardiac rhabdomyomata in tuberous sclerosis: their course and diagnostic value. Arch Dis Child 1989; 64: 196-200
120. Blute ML, Malek RS, Segura JW. Angiomyolipoma: clinical metamorphosis and concepts for management. J Urol 1988; 139: 20-4
121. Devroede G, Lemieux B, Masse S, et al. Colonic hamartomas in tuberous sclerosis. Gastroenterology 1988; 94: 182-8
122. Roach ES, DiMario FJ, Kandt RS, et al. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol 1999; 14: 401-7
123. Robbins TO, Bernstein J. Renal involvement. In: Gomez MR, editor. Tuberous sclerosis. New York (NY): Raven Press, 1988: 133-146
124. Pasyk KA, Argenta LC. Argon laser surgery of skin lesions in tuberous sclerosis. Ann Plast Surg 1988; 20: 426-33
125. Barax CN, Lebwohl M, Phelps RG. Multiple hamartoma syndrome. J Am Acad Dermatol 1987; 17: 342-6
126. Vega A, Torres J, Torres M, et al. A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease. J Invest Dermatol 2003; 121: 1356-9
127. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7
128. Schaller J, Rohwedder A, Burgdorf WH, et al. Identification of human papillomavirus DNA in cutaneous lesions of Cowden syndrome. Dermatology 2003; 207: 134-40
129. Starink TM. Cowden's disease: analysis of fourteen new cases. J Am Acad Dermatol 1984; 11: 1127-41
130. Fistarol SK, Anliker MD, Itin PH. Cowden disease or multiple hamartoma syndrome -cutaneous clue to internal malignancy. Eur J Dermatol 2002; 12: 411-21
131. Gorlin R. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995; 13: 113-25
132. Winkler PA, Guyuron B. Multiple metastases from basal cell naevus syndrome. Br J Plast Surg 1987; 40: 528-31
133. Schultz-Butulis BA, Gilson R, Farley M, et al. Nevoid basal cell carcinoma syndrome and non-Hodgkin's lymphoma. Cutis 2000; 66: 35-8
134. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to putative tumor suppressor gene on chromosome 9. Cell 1992; 69: 111-7
135. Xie J, Johnson RL, Zhang X, et al. Mutations of the PATCHED gene in several types of sporadic extracutaneous tumors. Cancer Res 1997; 57: 2369-72
136. Kopera D, Cerroni L, Fink-Puches R, et al. Different treatment modalities for the management of a patient with the nevoid basal cell carcinoma syndrome. J Am Acad Dermatol 1996; 34: 937-9
137. Gardner EJ. A genetic and clinic study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet 1951; 3: 167-76
138. Narisawa Y, Kohda H. Cutaneous cysts of Gardner's syndrome are similar to follicular stem cells. J Cutan Pathol 1995; 22: 115-21
139. Greenberg D, McIntyre H, Ramsaroop R, et al. Aggressive fibromatosis of the breast: a case report and literature review. Breast J 2002; 8: 55-7
140. Nandakumar G, Morgan JA, Silverberg D, et al. Familial polyposis coli: clinic manifestations, evaluation, management and treatment. Mt Sinai J Med 2004; 71: 384-91
141. Cruz-Correa M, Giardiello FM. Diagnosis and management of hereditary colon cancer. Gastroenterol Clin North Am 2002; 31: 537-49
142. Schreibman IR, Baker M, Amos C, et al. The hamartomatous polyposis syndromes: a clinic and molecular review. Am J Gastroenterol 2005; 100: 476-90
143. Hemminki A. The molecular basis and clinic aspects of Peutz-Jeghers syndrome. Cell Mol Life Sci 1999; 55: 735-50
144. Westerman AM, Wilson JH. Peutz-Jeghers syndrome: risks of a hereditary condition. Scand J Gastroenterol 1999; 230 Suppl.: 64S-70S
145. Harper PS, Harper RMJ, Howell-Evans AN. Carcinoma of the oesophagus with tylosis. Q J Med 1970; 39: 317-33
146. Griffiths WAD, Judge MR, Leigh IM. Disorders of keratinization. In: Champion RH, Burton JL, Burns DA, et al., editors. Rook/Wilkinson/Ebling textbook of dermatology. 6th ed. Oxford: Blackwell Science, 1998: 1483-1588
147. Adreev VC, Petkov I. Skin manifestations associated with tumours of the brain. Br J Dermatol 1975; 92: 675-8
148. Mercadante S, Villari P, Fulfaro F. Rifampicin in opioid-induced itching. Support Care Cancer 2001; 9: 467-8
149. Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3: 183-9